Seminars in Oncology
Volume 31, Issue 2 , Pages 185-197 , April 2004

The relationship of patient age to the pathobiology of the clonal myeloid diseases1

  • Marshall A Lichtman

      Affiliations

    • Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    • Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, USA
    • Corresponding Author InformationAddress reprint requests to Marshall A. Lichtman, MD, University of Rochester Medical Center, 601 Elmwood Ave, Box 610, Rochester, NY, 14642 USA
    • ,
  • Jacob M Rowe

      Affiliations

    • Department of Haematology and Bone Marrow Transplantation, Rambam Medical Center and the Technion Israel Institute of Technology, Haifa, Israel

References 

  1. Vardiman JW, Harris NL, Bruning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  2. Pui C-H, Raimondi SC, Srivastava DK, et al.  Prognostic factors in infants with acute myeloid leukemia. Leukemia. 2000;14:684–687
  3. Webb DKH, Harrison G, Stevens RF, et al.  Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2000;98:1714–1720
  4. Wells RJ, Arthur DC, Srivasta A, et al.  Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia (Children’s Cancer Group Study 213). Leukemia. 2002;16:601–607
  5. Aricò M, Biondi A, Pui C-H. Juvenile myelomonocytic leukemia. Blood. 1997;90:479–488
  6. McNally RJQ, Rowland D, Roman E, et al.  Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15:173–189
  7. Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human life span, implying only one rate-limiting mutation. Leukemia. 2000;14:722–726
  8. Rowley J, Alimena G, Garson OM, et al.  A collaborative study of the relationship of the morphological type of acute non lymphocytic leukemia with patient age and karyotype. Blood. 1982;59:1013–1022
  9. Aul C, Gatterman N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358–367
  10. Bauduer F, Ducout L, Dastugue N, et al.  Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res. 1998;22:205–208
  11. Christolini A, Mazzuccout MG, Ferrari A, et al.  Essential thrombocythemia. Hematologica. 1990;75:537–540
  12. Gruppo Italiano Studio Policitemia . Polycythemia vera (The natural history of 1,213 patients followed for 20 years). Ann Intern Med. 1995;123:656–664
  13. Bloomfield CD, Shuma C, Regal L, et al.  Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80(suppl S):2191–2198
  14. Grinwade D, Walker H, Oliver F, et al.  The importance of diagnostic cytogenetics on outcome in AML (Analysis of 1612 patients entered into the MRC AML 10 trial). Blood. 1998;92:2322–2333
  15. Slovak ML, Kopecky KJ, Cassileth PA, et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia (a Southwest Oncology Group/Eastern Cooperative Oncology Group study). Blood. 2000;96:4075–4083
  16. Grinwade D, Walker H, Harrison G, et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML) (Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial). Blood. 2001;98:1312–1320
  17. Schoch C, Haferlach T, Haase D, et al.  Patients with de novo acute myeloid leukemia and complex karyotypic aberrations show a poor prognosis despite intensive treatment, a study of 90 patients. Br J Haematol. 2001;112:118–126
  18. Rossi C, Pelizzari AM, Bellotti D, et al.  Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000;14:636–641
  19. Byrd JC, Mrózek K, Dodge RK, et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia (Results from Cancer and Leukemia Group B (CALGB 8461)). Blood. 2002;100:4325–4336
  20. Schoch C, Kern W, Krawitz P, et al.  Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood. 2001;98:3500; (letter)
  21. Moorman AV, Roman E, et al.  Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukemia. Br J Cancer. 2002;86:1061–1063
  22. Neubauer A, Dodge RK, George SL, et al.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603–1611
  23. Coglan DW, Morley AA, Matthews JP, et al.  The incidence and prognostic significance of mutations in codon 13 of the n-ras gene in acute myeloid leukemia. Leukemia. 1994;8:1682–1687
  24. Wattel E, Preudhomme C, Hecquet B, et al.  p53 gene mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148–3157
  25. Yokota S, Kiyoi H, Nakao M, et al.  Internal tandem duplication of the FLT 3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies (A study on a large series patients and cell lines). Leukemia. 1997;11:1605–1609
  26. Kottaridis PD, Gale RE, Frew ME, et al.  The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy (Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials). Blood. 2001;98:1752–1759
  27. Abu-Duhier FM, Goodever AC, Willson JA, et al.  FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190–195
  28. Rombouts WJ, Blokland I, Lowenberg B, et al.  Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplication in the flt3 gene. Leukemia. 2000;14:675–683
  29. Fröhling S, Schlenk RF, Beitruck J, et al.  Prognostic significance of activating FLT3 mutations in younger adults (16–60 years) with acute myeloid leukemia and normal cytogenetics (A study of the AML Study Group Ulm). Blood. 2002;100:4372–4380
  30. Stirewalt DL, Kopecky KJ, Meshinchi S, et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–3595
  31. Kiyoi H, Naoe T, Nakano Y, et al.  Prognostic implications of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–3080
  32. Nørgaard JM, Langkjer ST, Palshof T, et al.  Relation of blast cell survival to chemotherapy resistance in AML. Br J Haematol. 1996;93:888–897
  33. Banker DE, Groudine M, Norwood T, et al.  Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89:243–255
  34. Garrido SM, Cooper JJ, Appelbaum FR, et al.  Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res. 2001;25:23–32
  35. Leith CP, Kopecky KJ, Godwin J, et al.  Acute myeloid leukemia in the elderly (Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study). Blood. 1997;89:3323–3329
  36. Leith CD, Kopecky KJ, Chen I-M, et al.  Frequency and clinical significance of the expression of the multidrug resistance protein MDR1/P glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwestern Oncology Group study. Blood. 1999;94:1086–1099
  37. Nørgaard JM, Olesen G, Kristensen JS, et al.  Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol. 1999;68:219–228
  38. Fialkow PJ, Singer JW, Raskind WH, et al.  Clonal development, stem cell differentiation, and clinical remission in acute non-lymphocytic leukemia. N Engl J Med. 1987;317:468–473
  39. Turhan AG, Lemoine FM, Debert C, et al.  Highly purified primitive hematopoietic cells are PML-RARα negative and generate non-clonal progenitors in acute promyelocytic leukemia. Blood. 1995;85:2154–2161
  40. Vendetti A, Del Poeta G, Buccisano F, et al.  Biologic features of acute myeloid leukemia in the elderly. Blood. 1998;92:697–699
  41. Suárez L, Belén Vidriales M, Garcı́a-Laraña J, et al.  Multiparametric analysis of apoptotic and multidrug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica. 2001;86:1287–1295
  42. Baudard M, Marie JP, Cadiou M, et al.  Acute myelogenous leukaemia in the elderly (Retrospective study of 235 consecutive patients). Br J Haematol. 1994;86:82–91
  43. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670–1673
  44. Johnson PRE, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia. Leuk Lymph. 1994;16:51–56
  45. Stein RS, Wolff SN, Greer JP, et al.  Age and cytogenetics as predictors of event free survival in patients with acute non-lymphoid leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy. Leuk Lymph. 2001;42:913–922
  46. Menzin J, Lang K, Earle CC, et al.  The outcome and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597–1603
  47. Åström M, Bodin L, Nilsson I, et al.  Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer. 2000;82:1387–1392
  48. Rowe JM. Treatment of acute myelogenous leukemia in older patients. Leukemia. 2000;14:480–487
  49. Latagliata R, Petti MC, Mandelli F. Acute myeloid leukemia in the elderly (“Peraspera ad astra”?). Leuk Res. 1999;23:603–613
  50. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly (Biology and therapeutic strategies). Crit Rev Oncol Hematol. 2001;39:275–287
  51. Hiddeman W, Kern W, Schoch C, et al.  Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569–3576
  52. Baudard M, Beauchamp-Nicoud A, Delman A, et al.  Has the prognosis for acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16 year period. Leukemia. 1999;13:1481–1490
  53. Ellison RR, Holland JF, Weil M, et al.  Arabinosyl cytosine (A useful agent in the treatment of acute leukemia in adults). Blood. 1968;33:507–523
  54. Yates JW, Wallace HJ, Ellison RR, et al.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chem Rep. 1973;57:485–488
  55. Feldman EJ, Seiter K, Damon L, et al.  A randomized trial of high-vs standard-dose mitoxantrone in elderly patients with acute myeloid leukemia. Leukemia. 1997;71:485–499
  56. Goodwin JE, Kopecky KJ, Head DR, et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia (A Southwest Oncology Group study (9031)). Blood. 1998;97:3607–3615
  57. Leone F, Ciolli S, Giuliani A, et al.  Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly (pharmacokinetic study and clinical results). Br J Haematol. 1995;90:169–174
  58. Manoharan A, Trickett A, Kwan YL, et al.  Flexible low intensity combination chemotherapy for elderly patients with acute myeloid leukemia. Int J Hematol. 2002;75:519–527
  59. Hartmann F, Jacobs G, Gotto H, et al.  Cytosine arabinoside, idarubicin, and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients. Leuk Lymphoma. 2001;42:347–355
  60. Letendre L, Noel P, Litzow MR, et al.  Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose Ara-C. Am J Clin Oncol. 1998;2:142–144
  61. Leone G, Sica S, Pagano L. Idarubicin including regimens in acute myelogenous leukemia in elderly patients. Crit Rev Oncol Hematol. 1999;32:59–68
  62. Heyll A, Aul C, Goglin F, et al.  Results of conventional dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia. Ann Hematol. 1994;68:279–283
  63. Jackson GH, Taylor PRA, Galloway MJ, et al.  The use of oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly (A report of toxicity and efficacy). Leukemia. 1997;11:1193–1196
  64. Löwenberg B, Suciu S, Archimbaud E, et al.  Mitoxantrone versus daunorubicin in induction consolidation chemotherapy-The value of low-dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly (Final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group randomized phase III study AML-9). J Clin Oncol. 1998;16:872–881
  65. Goldstone AH, Burnett AK, Wheatley K, et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients (The result of the United Kingdom Medical Research Council AML11 trial). Blood. 2001;98:1302–1311
  66. Rowe JM, Neuberg D, Freidenberg W, et al.  A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older patients (>55) with acute myelogenous leukemia(AML) (A study of the Eastern Cooperative Oncology Group (E3993)). Blood. 1998;92(suppl 1):1284a; abstr
  67. Wahlin A, Markevärn B, Golovleva I, et al.  Prognostic significance of risk group stratification in elderly patients with acute myeloid leukemia. Br J Haematol. 2001;115:25–33
  68. de Lima M, Ghjaddar H, Pierce S, et al.  Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996;93:89–95
  69. Ferrara F, Annunziata M, Capia C, et al.  Therapeutic options for patients over 75 years of age with acute myeloid leukemia. Haematologica. 1998;83:126–131
  70. Hernandez-Baluda JC, Sierra J, Esteve J, et al.  Treatment of elderly patients with AML (Results of an individual approach). Haematologica. 1998;83:34–39
  71. Stone RM, Berg DT, George SL, et al.  Postremission therapy in older patients with de novo acute myeloid leukemia (A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine). Blood. 2001;98:548–553
  72. Montillo M, Tedeschi A, Pagano L, et al.  Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia. A pilot study from the Gimema group. Br J Haematol. 2000;111:334–337
  73. Schiller GJ. Postremission therapy of acute myeloid leukemia in older adults. Leukemia. 1996;10(suppl 1):518–520
  74. Cahn JY, Labopin M, Mandelli F, et al.  Autologous bone marrow transplantation for first remission of acute myeloblastic leukemia in patients older than 50 years (A retrospective analysis of the European Bone Marrow Transplant Group). Blood. 1995;85:575–579
  75. Lyman GH, Balducci L, Agboola Y. Use of hematopoietic growth factors in older cancer patients. Oncol Spectrums. 2001;2:414–421
  76. Bokemeyer C, Honecker F, Wedding U, et al.  Use of hematopoietic growth factors in elderly [patients receiving cytotoxic chemotherapy. Onkologie. 2002;25:32–39
  77. Rowe JM, Liesveld JL. Hematopoietic growth factors in acute leukemia. Leukemia. 1997;11:328
  78. Bennett CL, Hynes D, Godwin J, et al.  Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML) (Estimates from a Southwest Oncology Group Trial). Cancer Invest. 2001;19:603–610
  79. Woronoff-Lemsi MC, Witz F, Arveux P, et al.  Intérêt thérapeutique et économique du GM-CSF dans le traitment des leucémies aiguës myéloblasiques du sujet âgé (Protocole GOELAM Sa3). Therapie. 2001;56:131–133
  80. Spataro V, Kovacsovics T, Bach S, et al.  Acute myeloid leukemia in the elderly (Results of an individualized approach in two centres). Leuk Lymph. 2000;39:521–530
  81. López A, de la Rubia J, Martı́n G, et al.  Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res. 2001;25:685–692
  82. Harousseau J-L. Acute myeloid leukemia in the elderly. Blood Rev. 1998;12:145–153
  83. Yoshida S, Kuriyama K, Miyazaki Y, et al.  De novo acute myeloid leukemia in the elderly (A consistent fraction of long-term survivors by standard-dose chemotherapy). Leuk Res. 2001;25:33–38
  84. Wahlin A, Makervarn B, Golovleva I, et al.  Improved outcome in adult acute myeloid leukemia in almost entirely restricted to young patients and associated with stem cell transplantation. Eur J Hematol. 2002;68:54–63
  85. Wick G, Grubeck-Loehenstein B. The aging immune system (Primary and secondary alterations of immune reactivity in the elderly). Exp Gerontol. 1997;32:401–413
  86. Latagliata R, Alimena G, Carmosino I, et al.  Conservative treatment for patients over 80 years with acute myelogenous leukemia. Am J Hematol. 2002;71:256–259
  87. Larson RA, Boogaerts M, Estey E, et al.  Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627–1636
  88. Chakraverty R, Peggs K, Chopra R, et al.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood. 2002;99:1071–1078
  89. Schlenk RF, Hartmann F, Hensel M, et al.  Less intense conditioning with fludarabine, cyclophosphamide, idarubicin, and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Leukemia. 2002;126:581–586
  90. Baer MR, George SL, Dodge RK, et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in primarily untreated patients over 60 years of age and older with acute myeloid leukemia (Cancer and Leukemia Group B study 9720). Blood. 2002;100:1224–1232
  91. Rossi HA, O’Donnell J, Sarcinelli FM, et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2002;16:310–315
  92. Saito K, Nakamura Y, Aoyagi M, et al.  Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol. 2000;71:238–244
  93. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies (New horizons in therapy). Blood. 2003;102:3880–3889
  94. Smith BD, Levis M, Brown P, et al.  Single agent CEP-701, a novel FLT-3 inhibitior, shows initial response in patients with refractory acute myeloid leukemia. Blood. 2002;100:85a
  95. Marucci G, Stock W, Klisovic I, et al.  In vivo activity of Genasense (G3139)(GS), a Bcl-2 antisense oligonucleotide in previously untreated patients >60 years with acute myeloid leukemia (AML) (Initial report of a phase I study in combination with daunorubicin and cytarabine). Blood. 2002;100:337a; (abstr)

PII: S0093-7754(03)00667-5

doi: 10.1053/j.seminoncol.2003.12.029

Seminars in Oncology
Volume 31, Issue 2 , Pages 185-197 , April 2004

Article Tools

* Image Usage & Resolution